Biological effects of AL622, a molecule rationally designed to release an EGFR and a c-Src kinase inhibitor

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Breast cancer progression involves oncogenes like c-Src and EGFR.
• These oncogenes can act independently or synergistically to drive tumor growth and invasion.
• Targeting these oncogenes is crucial for developing effective breast cancer therapies.

Purpose of the Study:

• To design and synthesize a novel molecule, AL622, targeting both c-Src and EGFR.
• To evaluate the antitumor potential of AL622 in preclinical models.
• To assess AL622's efficacy in blocking cancer cell proliferation, motility, and invasion.

Main Methods:

• Design of AL622, a dual-targeting molecule with a quinazoline head (EGFR) and a PP2-like structure (c-Src).
• Synthesis of AL622, with a failsafe hydrolysis to PP2 for c-Src inhibition.
• In vitro testing of AL622 potency in NIH3T3 and human breast cancer cell lines expressing EGFR, HER2, and c-Src.

Main Results:

• AL622 demonstrated potent inhibition of EGFR and c-Src signaling pathways.
• In EGFR/HER-2-driven cells, AL622 was more potent than PP2 alone.
• AL622 effectively blocked cancer cell motility and invasion, comparable to PP2 and combination therapies.

Conclusions:

• AL622 is a promising dual-targeting agent for breast cancer treatment.
• Its efficacy is particularly notable in tumors where c-Src and/or EGFR are key drivers.
• AL622 represents a potential advancement in antitumor therapy for relevant breast cancer subtypes.